NICE draft rejects Sanofi-Aventis's Multaq, but U-turns on Yondelis
24 December 2009
Elizabeth Sukkar
Please Login to read the full article.
24 December 2009
Elizabeth Sukkar
The UK's National Institute for Health and Clinical Excellence (NICE) has rejected the NHS use (in England and Wales) of Sanofi-Aventis's atrial fibrillation (AF) treatment, dronedarone (Multaq), in the first appraisal draft of the anti-arrhythmic drug.
However, in a separate...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Lack of "appropriate" evidence prompts NICE no for PharmaMar despite patient access plan
- Sanofi's Multaq hits another setback
- Patient access scheme prompts NICE U-turn on Novartis' Tasigna, while BMS will appeal against no for Sprycel
- NICE needs more info on Pradaxa before it can win warfarin replacement race
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
